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Abstract
In the summer of 2008, the ﬁrst case of Crimean–Congo haemorrhagic fever (CCHF) was observed in Greece. The laboratory diagnosis
was established using nested RT-PCR and quantitative real-time RT-PCR. A high viral load and increased levels of cytokines were
detected on the third day of illness and the patient died 7 days after the onset of symptoms. Nucleotide sequence analysis revealed that
the Greek CCHF virus strain had high sequence identity with other Balkan CCHF virus strains.
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Introduction
Crimean–Congo haemorrhagic fever (CCHF) is a severe viral
human disease with fatality rates up to 30% [1]. It is the most
widely disseminated tick-borne viral disease, with a geographi-
cal distribution following that of Hyalomma spp. ticks, the main
vectors of CCHF virus (CCHFV). With the 48 latitude as the
northern geographical limit, the disease is present from east-
ern China to Russia, the Balkans, Central Asia, and Africa.
Besides the tick bite, an additional mode of transmission is
direct contact of broken skin or mucous membranes with
blood or tissues of infected livestock or CCHF patients. Risk
groups include shepherds, farmers, soldiers, veterinarians, and
healthcare workers. CCHF is a signiﬁcant public health threat
because of the associated high fatality rate, the absence of an
FDA-approved vaccine, and the potential for human-to-human
transmission and nosocomial outbreaks.
CCHF is endemic in the Balkan peninsula [2–7]. Since 2002,
when the disease was ﬁrst detected in Turkey, 2508 conﬁrmed
CCHF cases have been reported in that country, involving 133
deaths, mainly in middle and eastern Anatolia [8]. CCHF cases
had not been reported in Greece prior to 2008. However, a
CCHFV strain (strain AP92) was isolated in 1975 from Rhipi-
chepahlus bursa ticks collected from goats in Vergina village,
northern Greece [9]. Antibodies against CCHFV were
detected in four of 64 residents of the prefecture where
strain AP92 was isolated; however, none of them recalled any
illness resembling CCHF [10]. A serosurvey revealed that 1%
of a human population had antibodies to CCHFV [11]. As no
CCHF case had been reported in Greece, it was suggested
that the human antibodies were against strain AP92, which
seems to be moderately pathogenic to humans, and thus a
good candidate for vaccine studies. Genetically, strain AP92
differs by more than 20% at the nucleotide level in the S RNA
segment from all other known CCHFV strains [3,5]. Here we
present the laboratory ﬁndings on the ﬁrst clinical CCHF case
in Greece with a fatal outcome.
The Case
On 21 June 2008, a 46-year-old woman was admitted to the
Alexandroupoli General University Hospital, with high fever
(39.5C), headache, chills, malaise, nausea, vomiting and
abdominal pain following a tick bite 4 days before [12]. The
patient was engaged in agricultural activities in a rural area,
2 km north of Komotini, a city in Rhodope prefecture, in
north-eastern Greece. The city is located at an altitude of
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32–38 m, close to the feet of the Rhodope mountains (lati-
tude 417¢22¢¢ N, longitude 2523¢47¢¢ E), and 18 km south of
the Greek–Bulgarian border (Fig. 1). The patient did not
report any travel abroad. Physical examination revealed mild
sensitivity during palpation of the right hypochondrium, and a
red papule at the site of tick bite was observed. Laboratory
examination on admission showed leukocytes at 5620/lL (ref-
erence range 4500–11 000/lL), with 81.4% neutrophils, a hae-
matocrit of 33.5%, platelets at 158 · 109/L, an aspartate
transaminase (AST) level of 139 IU/L (reference range
<31 IU/L), an alanine transaminase (ALT) level of 46 IU/L (ref-
erence range <34 IU/L), a c-glutamyl-transpeptidase level of
57 IU/L (reference range 9–38 IU/L), a lactate dehydrogenase
(LDH) level of 701 IU/L (reference range 25–248 IU/L), an
activated partial thromboplastin time (APTT) of 64.3 s (refer-
ence range 24–35 s), an International Normalized Ratio of
1.77 (reference range 0.68–1.17), and D-dimers above 10 000
ng/mL. A few hours after admission, blood re-examination
revealed that the platelet level was 100 · 109/L, the ARTT
was 82.6 s, and the ﬁbrinogen level was 227 mg/dL.
A chest X-ray showed a right lower lobe linear atelectasy
and bilateral pleural effusion. Echocardiography revealed mild
hepatomegaly without focal damage, gall bladder dilatation,
and the presence of pericholecystic oedema, as well as ﬂuid
collection in the Morrison and Douglas spaces. A computed
tomography scan of the abdomen revealed severe ascites
under pressure in the whole peritoneum, and liver enlarge-
ment. The blood supply was decreased in the arterial phase
of the examination. Remarkable oedema surrounding the
whole portal vein was seen.
Supportive treatment was initiated, combined with cepha-
losporins and metronidazole; in addition, doxycycline was
administered, as rickettsiosis was included in the differential
diagnosis. CCHF was not included in the initial differential
diagnosis.
On the next day, APTT could not be determined,
D-dimers were above 10 000 ng/mL, the AST level was
293 U/L, the ALT level was 95 U/L, and the LDH level was
1661 U/L. The patient developed disseminated intravascular
coagulation, and fresh frozen plasma was given.
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FIG. 1. Crimean–Congo haemorrhagic
fever virus S RNA-based phylogenetic
tree. Dugbe virus was used as the out-
group. The numbers at the nodes indi-
cate percentage bootstrap replicates of
100; values below 60% are not shown.
Horizontal distances are proportional to
the nucleotide differences. The scale bar
indicates 10% nucleotide sequence
divergence. Sequences in the tree are
indicated by GenBank accession number,
strain name, and country. The Greek
strain of the present study is given in
bold.
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On 23 June, the patient was afebrile and complained of
severe rachialgia. A petechial rash on the extremities was
seen, and she suffered heavy haemorrhage from the genital
tract, and diarrhoea, which became haemorrhagic.
Large haematomas were seen at the injection and veni-
puncture sites. Increased levels of transaminases (AST level
of 3962 U/L, and ALT level of 1545 U/L) and LDH (8085 U/
L), and an undeﬁnable APTT were detected. Serological
examination for hepatitis A, B and C was negative. On the
same day, oliguria, mental disturbance and severe lactic
acidosis were established. Bone marrow aspiration, which
was performed to exclude haematological malignancy,
revealed haemophagocytosis of neutrophils and erythrocytes
by histiocytes. No blastic inﬁltration was seen. The patient’s
condition deteriorated rapidly, and she was transferred to
the intensive-care unit, where she was intubated and given
inotrops, fresh frozen plasma, erythrocytes, corticosteroids,
and antithrombin III.
Convulsions were present and were attributed to a prob-
able intracranial haemorrhage. On 25 June (seventh day of
the disease), the patient died with multiple organ failure. An
autopsy was not performed (it was not approved by the
patient’s family).
Laboratory Diagnosis
Stored serum and blood specimens taken at the time of
admission (third day of the disease) were sent to Aristotle
University of Thessaloniki after the death of the patient. Viral
RNA was extracted by using a Viral RNA extraction kit
(Qiagen, Hilden, Germany). A nested RT-PCR that ampliﬁes
a 240-bp fragment of the S RNA genome segment of CCHFV
[13] was performed, and gave a positive result; sequencing of
the product of the nested PCR conﬁrmed the result (acces-
sion number EU871766). An additional 452-bp fragment of
the M RNA segment was ampliﬁed and sequenced (accession
number FJ643480). The sequences of the S and M segments
were aligned with the corresponding segments retrieved
from the GenBank database, using CLUSTAL W, and phylo-
genetic analysis was performed using the DNAdist, Neighbor
and Consence programs of the PHYLIP software. Analyses
showed that the causative CCHFV strain clusters in the
European/Turkish clade, together with other Balkan strains
(Figs 1 and 2). In the S segment, the Rodopi strain presents
the highest identity with the Balkan strains, differing from the
Russian strains by 3.1–4.4%, whereas the M segment is
genetically closer to that in the Russian strains than in the
Balkan strains (genetic distances of 4.6% and 7.4% respec-
tively). A quantitative real-time PCR [14] revealed a CCHFV
load of 2.97 · 108 copies/mL. No CCHFV antibodies were
detected.
To investigate the patient’s innate immune response, the
following details concerning cytokines, chemokines and
growth factors were obtained by using the BioPlex Human
Cytokine 27-plex panel in a Bio-plex suspension array system
(Bio-Rad Laboratories): interleukin (IL)-1b, IL-1 receptor
antagonist, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12,
IL-13, IL-15, IL-17, eotaxin, basic ﬁbroblast growth factor,
granulocyte colony-stimulating factor, granulocyte–macro-
phage colony-stimulating factor, interferon-c, interferon-
inducible protein-10, monocyte chemoattractant protein-1
(MCP-1), macrophage inﬂammatory protein-1a, macrophage
inﬂammatory protein-1b, platelet-derived growth factor-bb,
RANTES, tumour necrosis factor-a (TNF-a), and vascular
endothelial growth factor. A strong innate immune response
was observed, with increased expression of IL-6 (361.7 pg/mL),
IL-8 (480.6 pg/mL), IL-9 (52.2 pg/mL), IL-15 (63.1 pg/
mL), IL-1 receptor antagonist (41.1 pg/mL), TNF-a (53.7 pg/
mL), RANTES (65.5 pg/mL), eotaxin (25.2 pg/mL), interferon-
c (69.5 pg/mL), MCP-1 (382.5 pg/mL), and vascular endothe-
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FIG. 2. Crimean–Congo haemorrhagic fever virus (CCHFV) M
RNA-based phylogenetic tree. The AP92 CCHFV strain was used as
the outgroup. The numbers at the nodes indicate percentage boot-
strap replicates of 100; values below 60% are not shown. Horizontal
distances are proportional to the nucleotide differences. The scale
bar indicates 10% nucleotide sequence divergence. Sequences in the
tree are indicated by GenBank accession number, strain name, and
country. The Greek strain of the present study is given in bold.
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lial growth factor (30.1 pg/mL). The levels of the remaining
factors were below 10 pg/mL, and in healthy (control) indi-
viduals all respective factors were below 10 pg/mL.
Discussion
Although the Balkan peninsula has been known to be a
CCHF-endemic region since the early 1950s, no CCHF case
was reported in Greece prior to 2008. In the early spring of
2008, a cluster of CCHF cases was reported in Bulgaria, very
close to the Greek–Bulgarian border [15]. Additionally, in
the same year, many CCHF cases were observed in Turkey,
where, during January to June of 2008, 688 conﬁrmed cases
were reported, 5.96% of them fatal [8]. We cannot exclude
the possibility that unrecognized CCHF cases may have
occurred in previous years in Greece.
The patient had no underlying disease; the presentation
of severe illness and the rapid progression to death seem
to have been associated with a massive inﬂammatory
response and a catastrophic immune cascade. Increased lev-
els of IL-6 and TNF-a have been previously associated with
severe or fatal CCHF in humans [16,17]. Signiﬁcantly high
levels of MCP-1 were detected in our patient, suggesting
that MCP-1 plays an important role in the course and,
probably, in the outcome of the disease. In addition, high
levels of IL-8, one of the major mediators of the inﬂamma-
tory response and a major chemotaxis inducer, were
detected. Haemorrhages occurred on the ﬁfth day of the
disease. Haematuria, melena, gingival bleeding and bleeding
from the vagina may commence on days 4 and 5 of the ill-
ness [18]. Among the sites of bleeding, that from the vagina
accounts for 10%, and the most common haemorrhagic
manifestation is epistaxis [18].
Thrombocytopenia and prolonged APTT and International
Normalized Ratio were among the ﬁrst altered parameters.
Criteria predicting a fatal outcome, during the ﬁrst 5 days of
the disease, include the following: leukocytes ‡10 · 109/L,
platelets £20 · 109/L, AST ‡200 U/L or ALT ‡150 U/L,
APTT ‡60 s, and ﬁbrinogen £110 mg/dL [19]. Recently the
criterion of leukocyte counts was excluded, and the level of
transaminases was modiﬁed to AST ‡700 IU/L and ALT
‡ 900IU/L [20]. Our patient fulﬁlled all four modiﬁed criteria.
Recently, it was shown that a high CCHFV load is predictive
of fatal outcome [7,14,21]. The viral load of the patient on
the third day of the disease was 2.97 · 108 copies/mL. In
comparison, viral load of 3.45 · 109 copies/mL was observed
on the sixth day of illness in a fatal case in Albania, whereas
other primary cases who survived had viral loads ranging
from 3.9 · 103 to 8.6 · 107 copies/mL, and all secondary
cases had viral loads below 2.8 · 104 copies/mL [14]. It
could be suggested that a viral load greater than 1 · 108 cop-
ies/mL is associated with fatal outcome.
CCHFV IgM antibodies are detectable as early as day 4 of
illness in survivors [22]. In the present case, the available
serum specimen was taken on the third day of illness; it was
therefore not expected to detect CCHFV-speciﬁc antibodies.
In addition, an antibody response is rarely demonstrable in
fatal cases, the detection of antibodies being generally a
favourable sign [22].
The remarkable haemophagocytosis seen in our patient is
a phenomenon that has also been reported by other
researchers; it was suggested to play a role in the develop-
ment of pancytopenia in CCHF [23–25].
The patient did not report any travel abroad. She was
working in a tobacco plantation, and she had livestock very
close to her house. Dissemination of infected ticks, and
hence spread of CCHFV, is possible via the livestock trade
or movements of livestock or wild animals infested with
infected ticks. It was not possible to determine the exact ori-
gin and the conditions that inﬂuenced the emergence of
CCHF in Greece.
No secondary infections have been observed, probably
because haemorrhages started when the patient was already
hospitalized and all general precautions and protective mea-
sures had been taken. The situation would have been worse
if haemorrhagic manifestations had started before hospitaliza-
tion, when household members might have come into con-
tact with blood or excreta of the patient.
According to mathematical modelling of CCHFV transmis-
sion, if the ﬁrst infected person happens to die before he or
she has a chance to infect anyone else, an epidemic will not
occur [26]. Immediately after establishment of the laboratory
diagnosis, control measures were taken, coordinated by the
Hellenic Centre for Disease Control and Prevention [27].
In general, CCHF outbreaks have developed on a back-
ground of favourable climatic factors and environmental
changes that are beneﬁcial for the survival of large numbers
of Hyalomma ticks and of the hosts of both their immature
and adult stages [28]. In the northern hemisphere, Hyalomma
marginatum marginatum is activated by the rising temperature
in the spring. The mean temperature in Greece in April
2008 was high (18.1C), and rainfall was increased (67 mm)
in comparison with the dry April of 2007 (8 mm).
CCHFV has been detected in a variety of ixodid ticks, and
H. marginatum marginatum is considered to be the main vec-
tor. The Greek CCHFV strain AP92 was isolated from
R. bursa ticks [9]. It was suggested that the great genetic dif-
ference of that strain is related to the different genus of the
tick vector. However, in Turkey, CCHFV of the European/
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Turkish clade was detected in H. marginatum marginatum and
in R. bursa, with almost identical nucleotide sequences [29].
Although it is difﬁcult to incriminate an arthropod as an
actual vector, it seems that R. bursa plays an important role
in the CCHFV life cycle. Both tick species are abundant in
northern Greece, with H. marginatum marginatum and
R. bursa representing 12.8% and 19.8% of ticks, respectively
[30]. It cannot be predicted whether additional CCHF cases
will occur in the future in Greece. However, taking into
account that vectors are present in Greece and endemic foci
are present in neighbouring countries, and the emergence of
the disease in this country, it can be suggested that the risk
of more cases occurring in the future is high.
Clinicians should include CCHF in the differential diagnosis
of febrile syndromes accompanied by thrombocytopenia,
especially in regions neighbouring endemic countries and in
individuals returning from an endemic region. Detailed
knowledge of the medical history is very helpful. Effective
surveillance and reporting are necessary for the control of
CCHF, and require the collaboration of multidisciplinary
experts.
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